
zzso zzso incorporated into zzso zzso zzso such as zzso zzso has been shown to increase zzso zzso and reduce zzso by zzso tissue distribution in zzso zzso We have conducted a phase I clinical trial of zzso in 21 patients with zzso solid tumors (10 male, 11 female, median age: 53 years, median zzso 1, prior zzso therapy: 7 zzso A total of 32 courses at 28 day intervals were administered at 6 dose levels zzso 30, 45, 60, 75 and 90 zzso The drug was given as a 10 minute IV infusion on day 1 to the first 5 zzso 2 of them presented a grade 2 allergic reaction zzso zzso during infusion, which was rapidly zzso once drug administration was zzso zzso in the other 16 patients, the administration was modified to a 60 minute zzso zzso diluted in 250 zzso of zzso zzso only 1 patient presented the same allergic zzso Grade 2 fever and vomiting occurred in 9 patients and 7 patients respectively during the first 24 h after zzso There was no cardiac toxicity among the 18 zzso zzso Grade 3 or 4 zzso toxicity occurred at the 75 and 90 zzso dose zzso The dose limiting toxicity was zzso The maximum tolerated dose was 90 zzso and the recommended phase II dose was 75 zzso A zzso evaluation of zzso was conducted in 3 patients each at a different dose level zzso 60 and 75 zzso and was compared with free zzso given to the same patients in the same zzso 

